The Pathology of Type 2 Inflammation-Associated Itch in Atopic Dermatitis

Overview

Journal Diagnostics (Basel)

Specialty Radiology

Date 2021 Nov 27

PMID 34829437

Citations 9

Authors

Catharina Sagita Moniaga

Mitsutoshi Tominaga

Kenji Takamori

Affiliations

Soon will be listed here.

Abstract

Accumulated evidence on type 2 inflammation-associated itch in atopic dermatitis has recently been reported. Crosstalk between the immune and nervous systems (neuroimmune interactions) is prominent in atopic dermatitis research, particularly regarding itch and inflammation. A comprehensive understanding of bidirectional neuroimmune interactions will provide insights into the pathogenesis of itch and its treatment. There is currently no agreed cure for itch in atopic dermatitis; however, increasing numbers of novel and targeted biologic agents have potential for its management and are in the advanced stages of clinical trials. In this review, we summarize and discuss advances in our understanding of type 2 inflammation-associated itch and implications for its management and treatment in patients with atopic dermatitis.

Citing Articles

Biomarkers in Atopic Dermatitis: A Review of the Role of IL-13 and the Impact of Tralokinumab Treatment.

Gorelick J, Nguyen A, Schneider S, Martel B, Madsen D, Armstrong A Am J Clin Dermatol. 2025; 26(2):199-211.

PMID: 39820896 PMC: 11850464. DOI: 10.1007/s40257-024-00913-9.

Update on the pathogenesis of atopic dermatitis.

Criado P, Miot H, Bueno-Filho R, Ianhez M, Criado R, Silva de Castro C An Bras Dermatol. 2024; 99(6):895-915.

PMID: 39138034 PMC: 11551276. DOI: 10.1016/j.abd.2024.06.001.

Parnassin, a Novel Therapeutic Peptide, Alleviates Skin Lesions in a DNCB-Induced Atopic Dermatitis Mouse Model.

Hwang-Bo J, Veerappan K, Moon H, Lee T, Lee K, Park J Biomedicines. 2023; 11(5).

PMID: 37239060 PMC: 10216559. DOI: 10.3390/biomedicines11051389.

The hidden sentinel of the skin: An overview on the role of interleukin-13 in atopic dermatitis.

Napolitano M, di Vico F, Ruggiero A, Fabbrocini G, Patruno C Front Med (Lausanne). 2023; 10:1165098.

PMID: 37144036 PMC: 10151557. DOI: 10.3389/fmed.2023.1165098.

Dupilumab for treatment of severe atopic dermatitis accompanied by lichenoid amyloidosis in adults: Two case reports.

Zhao X, Zhu W, Mou Y, Xu M, Xia J World J Clin Cases. 2023; 11(10):2301-2307.

PMID: 37122507 PMC: 10131009. DOI: 10.12998/wjcc.v11.i10.2301.

References

Tojima I, Matsumoto K, Kikuoka H, Hara S, Yamamoto S, Shimizu S . Evidence for the induction of Th2 inflammation by group 2 innate lymphoid cells in response to prostaglandin D and cysteinyl leukotrienes in allergic rhinitis. Allergy. 2019; 74(12):2417-2426. DOI: 10.1111/all.13974. View

Olsson M, Bajpai R, Wee L, Yew Y, Koh M, Thng S . The cost of childhood atopic dermatitis in a multi-ethnic Asian population: a cost-of-illness study. Br J Dermatol. 2019; 182(5):1245-1252. DOI: 10.1111/bjd.18442. View

Nakagawa H, Nemoto O, Igarashi A, Saeki H, Murata R, Kaino H . Long-term safety and efficacy of delgocitinib ointment, a topical Janus kinase inhibitor, in adult patients with atopic dermatitis. J Dermatol. 2019; 47(2):114-120. PMC: 7028108. DOI: 10.1111/1346-8138.15173. View

Suarez-Farinas M, Tintle S, Shemer A, Chiricozzi A, Nograles K, Cardinale I . Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol. 2011; 127(4):954-64.e1-4. PMC: 3128983. DOI: 10.1016/j.jaci.2010.12.1124. View

Soumelis V, Reche P, Kanzler H, Yuan W, Edward G, Homey B . Human epithelial cells trigger dendritic cell mediated allergic inflammation by producing TSLP. Nat Immunol. 2002; 3(7):673-80. DOI: 10.1038/ni805. View

Tanimoto A, Ogawa Y, Oki C, Kimoto Y, Nozawa K, Amano W . Pharmacological properties of JTE-052: a novel potent JAK inhibitor that suppresses various inflammatory responses in vitro and in vivo. Inflamm Res. 2014; 64(1):41-51. PMC: 4286029. DOI: 10.1007/s00011-014-0782-9. View

Dillon S, Sprecher C, Hammond A, Bilsborough J, Rosenfeld-Franklin M, Presnell S . Interleukin 31, a cytokine produced by activated T cells, induces dermatitis in mice. Nat Immunol. 2004; 5(7):752-60. DOI: 10.1038/ni1084. View

Sugita K, Altunbulakli C, Morita H, Sugita A, Kubo T, Kimura R . Human type 2 innate lymphoid cells disrupt skin keratinocyte tight junction barrier by IL-13. Allergy. 2019; 74(12):2534-2537. DOI: 10.1111/all.13935. View

Wong L, Wu T, Lee C . Inflammatory and Noninflammatory Itch: Implications in Pathophysiology-Directed Treatments. Int J Mol Sci. 2017; 18(7). PMC: 5535975. DOI: 10.3390/ijms18071485. View

10.

Halvorsen J, Lien L, Dalgard F, Bjertness E, Stern R . Suicidal ideation, mental health problems, and social function in adolescents with eczema: a population-based study. J Invest Dermatol. 2014; 134(7):1847-1854. DOI: 10.1038/jid.2014.70. View

11.

Petra A, Tsilioni I, Taracanova A, Katsarou-Katsari A, Theoharides T . Interleukin 33 and interleukin 4 regulate interleukin 31 gene expression and secretion from human laboratory of allergic diseases 2 mast cells stimulated by substance P and/or immunoglobulin E. Allergy Asthma Proc. 2018; 39(2):153-160. PMC: 5827155. DOI: 10.2500/aap.2018.38.4105. View

12.

Cevikbas F, Wang X, Akiyama T, Kempkes C, Savinko T, Antal A . A sensory neuron-expressed IL-31 receptor mediates T helper cell-dependent itch: Involvement of TRPV1 and TRPA1. J Allergy Clin Immunol. 2013; 133(2):448-60. PMC: 3960328. DOI: 10.1016/j.jaci.2013.10.048. View

13.

Neill D, Wong S, Bellosi A, Flynn R, Daly M, Langford T . Nuocytes represent a new innate effector leukocyte that mediates type-2 immunity. Nature. 2010; 464(7293):1367-70. PMC: 2862165. DOI: 10.1038/nature08900. View

14.

Nattkemper L, Tey H, Valdes-Rodriguez R, Lee H, Mollanazar N, Albornoz C . The Genetics of Chronic Itch: Gene Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. J Invest Dermatol. 2018; 138(6):1311-1317. DOI: 10.1016/j.jid.2017.12.029. View

15.

Silverberg J, Toth D, Bieber T, Alexis A, Elewski B, Pink A . Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2020; 184(3):450-463. PMC: 7986183. DOI: 10.1111/bjd.19573. View

16.

Suarez-Farinas M, Dhingra N, Gittler J, Shemer A, Cardinale I, de Guzman Strong C . Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. J Allergy Clin Immunol. 2013; 132(2):361-70. PMC: 3991240. DOI: 10.1016/j.jaci.2013.04.046. View

17.

Czarnowicki T, He H, Canter T, Han J, Lefferdink R, Erickson T . Evolution of pathologic T-cell subsets in patients with atopic dermatitis from infancy to adulthood. J Allergy Clin Immunol. 2019; 145(1):215-228. PMC: 6957229. DOI: 10.1016/j.jaci.2019.09.031. View

18.

Chinthrajah S, Cao S, Liu C, Lyu S, Sindher S, Long A . Phase 2a randomized, placebo-controlled study of anti-IL-33 in peanut allergy. JCI Insight. 2019; 4(22). PMC: 6948865. DOI: 10.1172/jci.insight.131347. View

19.

Gauvreau G, OByrne P, Boulet L, Wang Y, Cockcroft D, Bigler J . Effects of an anti-TSLP antibody on allergen-induced asthmatic responses. N Engl J Med. 2014; 370(22):2102-10. DOI: 10.1056/NEJMoa1402895. View

20.

Salimi M, Barlow J, Saunders S, Xue L, Gutowska-Owsiak D, Wang X . A role for IL-25 and IL-33-driven type-2 innate lymphoid cells in atopic dermatitis. J Exp Med. 2013; 210(13):2939-50. PMC: 3865470. DOI: 10.1084/jem.20130351. View